Education Session

EDUCATION SESSION

08:00 – 09:30 and 14:15 – 15:45, Hall A

MYELOPROLIFERATIVE DISORDERS (MPD)

Chair: T Barbui (Azienda Ospedaliera Ospedali Riuniti di Bergamo,
Bergamo, Italy)

• BIOLOGICAL BASIS OF MPD

  R Skoda (University Hospital Basel, Basel, Switzerland)

• DEVELOPMENTS OF NOVEL THERAPIES IN MPD

  S Verstovsek (The University of Texas MD Anderson Cancer Center, Houston, TX, USA)

• LESSONS FROM THE PT-11 STUDY

  C Harrison (Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom)

EDUCATION SESSION

08:00 – 09:30 and 14:15 – 15:45, Hall C

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Chair: P Ghia (Università Vita-Salute San Raffaele, Milano, Italy)

• THE ROLE OF ANTIGENIC STIMULATION IN CLL PATHOGENESIS

  K Stamatopoulos (G. Papanicolaou Hospital, Thessaloniki, Greece)

• GENETIC MARKERS OF PROGNOSIS IN CLL

  A Pettitt (University of Liverpool, Liverpool, United Kingdom)

• NOVEL ANTIBODIES AND IMMUNOMODULATORS FOR THE THERAPY OF CLL

  E Montserrat (Hospital Clinic, Barcelona, Spain)

EDUCATION SESSION

08:00 – 09:30 and 14:15 – 15:45, Hall E

ACUTE MYELOID LEUKEMIA (AML)

Chair: T Robak (Medical University of Lodz, Lodz, Poland)

• MOLECULAR BASIS OF AML

  L Bullinger (University of Ulm, Ulm, Germany)

• NOVEL THERAPIES IN AML

  A Burnett (School of Medicine, Cardiff University, Cardiff, United Kingdom)

• TREATMENT OF ADULT AML

  FR Appelbaum (Fred Hutchinson Cancer Research Center, Seattle, Washington, USA)

EDUCATION SESSION

08:00 – 09:30 and 14:15 – 15:45, Hall D

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Chair: A Rosenwald (University of Würzburg, Würzburg, Germany)

• MOLECULAR PATHOGENESIS OF DLBCL

  G Lenz (Charité – Universitätsmedizin Berlin, Berlin, Germany)

• TARGETING ONCOGENIC PATHWAYS IN DLBCL

  F Morschhauser (Hopital Claude Huriez, Centre Hospitalier
  Universitaire de Lille, Lille, France)

• TREATMENT OF EXTRANODAL DLBCL

  E Zucca (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland)

EDUCATION SESSION

08:00 – 09:30 and 14:15 – 15:45, Hall F

THROMBOSIS

Chair: J Conard (Hotel-Dieu University hospital, Paris, France)

• THROMBUS FORMATION: THE ROLES OF FLOW AND TISSUE FACTOR

  J Heemskerk (CARIM, Maastricht University, Maastricht, The Netherlands)

• COAGULATION AS A TARGET FOR CANCER THERAPY

  J Ware (University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA)

• DIAGNOSIS AND MANAGEMENT OF CANCER RELATED THROMBOSIS

  A Lee (Vancouver General Hospital, Vancouver, British Columbia, Canada)

EDUCATION SESSION

08.00 - 09.30 and 14.15 - 15.45, Hall G

HEMOGLOBINOPATHIES

Chair: SL Thein (King’s College London School of Medicine/King’s College Hospital, London, United Kingdom)

• THALASSEMIA INTERMEDIA-TREATMENT STRATEGIES

  A Taher (American University of Beirut Medical Center, Beirut, Lebanon)

• HYPERCOAGULIBILITY IN SICKLE CELL DISEASE

  JJB Schnog (Sint Elisabeth Hospital, Willemstad, Curaçao, Netherlands Antilles)

• CARDIOVASCULAR COMPLICATIONS OF SICKLE CELL DISEASE

  G Gibbs (Imperial College London and Hammersmith Hospital, London, United Kingdom)

EDUCATION SESSION

08:00 – 09:30 and 14:15 – 15:45, Hall M

SUPPORTIVE CARE IN STEM CELL TRANSPLANTATION (SCT)

Chair: M Björkholm (Karolinska University Hospital and Institut, Stockholm, Sweden)

• MANAGEMENT & DIAGNOSIS OF CMV INFECTION

  H Einsele (University Hospital Würzburg, Würzburg, Germany)

• DIAGNOSIS & MANAGEMENT OF FUNGAL INFECTION

  G Maschmeyer (Klinikum Ernst von Bergmann, Potsdam, Germany)

• VACCINATION OF STEM CELL TRANSPLANT RECIPIENTS

  P Ljungman (Karolinska University Hospital, Stockholm, Sweden)

EDUCATION SESSION

08.00 – 09:30 and 14:15 – 15:45, Hall L

BIOMARKERS OF VASCULAR DISEASE

Chair: M Greaves (University of Aberdeen, Abderdeen, United Kingdom)

• THE PLATELET SHEDDOME

  L Brass (University of Pennsylvania, Philadelphia, USA)

• HOW TO DETECT AND MEASURE MICROPARTICLES

  P Harrison (Churchill Hospital, Oxford, United Kingdom)

• GPVI SHEDDING

  M Berndt (University College Cork, Cork, Ireland)

EDUCATION SESSION

08:00 – 09:30 and 14:15 – 15:45, Hall N

RED CELL DISEASE

Chair: M Cazzola (University of Pavia Medical School, Pavia, Italy)

• BIOLOGICAL FUNCTIONS AND NEW DEVELOPMENTS OF ERYTHROPOIESIS-STIMULATING AGENTS IN MANAGEMENT OF ANEMIA

  I MacDougall (King’s College Hospital, London, United Kingdom)

• BIOLOGICAL BASIS OF PNH

  L Luzzatto (Istituto Toscano Tumori, Firenze, Italy)

• MANAGEMENT OF PNH

  A Hill (Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom)

EDUCATION SESSION

09:45 – 11:15 and 16:00 - 17:30, Hall A

MYELODYSPLASTIC SYNDROMES (MDS)

Chair: L Malcovati (University of Pavia, S. Matteo Hospital, Pavia, Italy)

• BIOLOGICAL BASIS OF MDS

  JH Jansen (Radboud University Nijmegen Medical Centre, Nijmegen,
  The Netherlands)

• EPIGENETIC TREATMENT STRATEGIES IN MDS

  M Lübbert (University of Freiburg Medical Center, Freiburg, Germany)

• MANAGEMENT OF MDS

  P Fenaux (Hôpital Avicenne/ Paris 13 University, Bobigny, France)

EDUCATION SESSION

09:45 – 11:15 and 16:00 – 17:30, Hall C

MULTIPLE MYELOMA

Chair: M Cavo (“Seràgnoli” Institute of Hematology, Bologna, Italy)

• IMPACT OF MYELOMA BIOLOGY IN DISEASE OUTCOME

  H Avet-Loiseau (University Hospital, Nantes, France)

• RISK ADAPTED TREATMENT

  K Stewart (Mayo Clinic, Scottsdale, USA)

• TREATMENT OF DISEASE COMPLICATIONS AND UNUSUAL FORMS OF MYELOMA

  M Delforge (University Hospital Leuven, Leuven, Belgium)

EDUCATION SESSION

09:45 – 11:15 and 16:00 – 17:30, Hall E

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Chair: H Dombret (Hôpital Saint-Louis, Paris, France)

• ROLE OF ONCOGENIC MUTATIONS AND FUSION GENES IN ALL

  J Cools (K.U.Leuven - VIB, Leuven, Belgium)

• MRD ORIENTED TREATMENT IN PH-ADULT ALL

  JM Ribera (ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Spain)

• TREATMENT IN PH-ADULT ALL

  O Ottmann (Medizinische Klinik II, Klinikum der Goether Universität, Frankfurt/Main, Germany)

EDUCATION SESSION

09:45 – 11:15 and 16:00 – 17:30, Hall D

CHRONIC MYELOID LEUKEMIA (CML)

Chair: J Goldman (Imperial College London, London, United Kingdom)

• MOLECULAR BASIS OF CML

  J Melo (University of Adelaide, Adelaide, Australia)

• MOLECULAR DESIGN OF TARGETED THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA

  FX Mahon (INSERM U876 université victor Segalen CHU de Bordeaux,
  Bordeaux, France)

• TREATMENT OF CML

  S O'Brien (National Institiute for Cancer Research, Newcastle upon Tyne, United Kingdom)

EDUCATION SESSION

09:45 – 11:15 and 16:00 – 17:30, Hall F

T-CELL LYMPHOMA

Chair: C Gisselbrecht (Hôpital Saint Louis, Paris, France)

• PATHOLOGY AND PATHOGENESIS OF T-CELL LYMPHOMA

  P Gaulard (Hôpital Henri Mondor, CRETEIL Cedex, France)

• NEW TARGETS AND DRUGS IN PERIPHERAL T-CELL LYMPHOMA

  O O'Connor (NYU Langone Medical Center, New York, USA)

• FIRST-LINE TREATMENT IN PERIPHERAL T-CELL LYMPHOMAS

  F d'Amore (Aarhus University Hospital, Aarhus C, Denmark)

EDUCATION SESSION

09:45 – 11:15 and 16:00 – 17:30, Hall G

STEM CELL TRANSPLANTATION (SCT)

Chair: G Socié (Hopital Saint Louis, Paris, France)

• ROLE OF SCT IN MANAGEMENT OF LYMPHOMA

  A Sureda (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

• ROLE OF SCT IN MANAGEMENT OF MYELOMA

  JL Harousseau (Rene Gauducheau Cancer Centre, Nantes, France)

• ROLE OF SCT IN MANAGEMENT OF AML

  J Cornelissen (Erasmus MC, Daniel den Hoed, Rotterdam, The Netherlands)

EDUCATION SESSION

09:45 – 11:15 and 16:00 – 17:30, Hall G

STEM CELL TRANSPLANTATION (SCT)

Chair: G Socié (Hopital Saint Louis, Paris, France)

• ROLE OF SCT IN MANAGEMENT OF LYMPHOMA

  A Sureda (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

• ROLE OF SCT IN MANAGEMENT OF MYELOMA

  JL Harousseau (Rene Gauducheau Cancer Centre, Nantes, France)

• ROLE OF SCT IN MANAGEMENT OF AML

  J Cornelissen (Erasmus MC, Daniel den Hoed, Rotterdam, The Netherlands)

EDUCATION SESSION

09:45 – 11:15 and 16:00 – 17:30, Hall M

PET FOR LYMPHOMA MANAGEMENT

Chair: L Kostakoglu (Mount Sinai Medical Center, New York, USA)

• PET IN PEDIATRIC LYMPHOMA

  M Hutchings (Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark)

• PET-RESPONSE ADAPTED CLINICAL TRIALS

  A Gallamini (Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy)

• PET-NETWORK FOR CLINICAL TRIALS

  M Meignan (CHU Henri Mondor, APHP, Paris East University, Creteil, France)

EDUCATION SESSION

09:45 – 11:15 and 16:00 – 17:30, Hall L

TRANSFUSION

Chair: E van der Schoot (Sanquin Blood Supply Foundation, Amsterdam, The Netherlands)

• ABO BLOOD GROUP ANTIGENS

  M Olsson (Lund University, Lund, Sweden)

• HUMAN PLATELET ALLOANTIBODIES

  S Santoso (Justus-Liebig University Giessen, Giessen, Germany)

• CLINICAL TRIALS IN TRANSFUSION MEDICINE

  A Mijovic (King’s College Hospital, London, United Kingdom)

EDUCATION SESSION

09:45 – 11:15 and 16:00 – 17:30, Hall N

BLEEDING DISORDERS

Chair: I Peake (University of Sheffield, Sheffield, United Kingdom)

• EUROPEAN REGISTRY OF RARE BLEEDING DISORDERS

  F Peyvandi (IRCCS Maggior Hospital Foundation, University of Milan, Milan, Italy)

• FACTOR XI DEFICIENCY

  U Seligsohn (Chaim Sheba Medical Center, Ramat Gan, Israel)

• TYPE 3 VON WILLEBRAND DISEASE

  F Leebeek (Erasmus MC, Rotterdam, The Netherlands)